Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Sanofi-Aventis Sa (SNY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 104,924,880
  • Shares Outstanding, K 2,574,210
  • Annual Sales, $ 38,710 M
  • Annual Income, $ 4,898 M
  • 36-Month Beta 0.97
  • Price/Sales 2.74
  • Price/Book 1.71

Price Performance

See More
Period Period Low Period High Performance
39.03 +3.19%
on 12/21/16
41.77 -3.58%
on 01/12/17
+1.41 (+3.64%)
since 12/20/16
36.81 +9.41%
on 10/26/16
42.42 -5.06%
on 11/10/16
+2.20 (+5.79%)
since 10/20/16
36.81 +9.41%
on 10/26/16
44.50 -9.49%
on 04/21/16
-0.06 (-0.14%)
since 01/20/16

Most Recent Stories

More News
Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of...

Key FDA Events to Watch Out for in Q1

Two important regulatory events scheduled in the first quarter of 2017.

Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche’s, Sanofi and Regeneron Pharmaceuticals

Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit

Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.

The FDA Approved Fewer Drugs in 2016: Here's Why

Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regeneron from Selling their Cholesterol Drug in the US

LONDON, UK / ACCESSWIRE / January 9, 2017 / Active Wall St. blog coverage looks at the headline from Amgen Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi SA (NYSE: SNY)....

Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Support & Resistance

2nd Resistance Point 40.55
1st Resistance Point 40.36
Last Price 40.28
1st Support Level 39.99
2nd Support Level 39.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.